Hansa Biopharma AB Share Price BOERSE MUENCHEN

Equities

24H

SE0002148817

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN 01:13:12 08/06/2024 am IST 5-day change 1st Jan Change
4.378 EUR -0.45% Intraday chart for Hansa Biopharma AB +0.74% +79.57%

Financials

Sales 2024 * 24Cr 2.27Cr 2.1Cr 189.63Cr Sales 2025 * 34Cr 3.25Cr 3.01Cr 271.62Cr Capitalization 322.99Cr 31Cr 28Cr 2.56TCr
Net income 2024 * -74Cr -6.98Cr -6.46Cr -582.63Cr Net income 2025 * -71Cr -6.76Cr -6.26Cr -564.4Cr EV / Sales 2024 * 15.5 x
Net Debt 2024 * 47Cr 4.5Cr 4.17Cr 375.74Cr Net Debt 2025 * 73Cr 6.96Cr 6.44Cr 581.34Cr EV / Sales 2025 * 11.6 x
P/E ratio 2024 *
-4.44 x
P/E ratio 2025 *
-5.27 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
1 week+0.74%
Current month+0.74%
1 month+74.70%
3 months+57.48%
6 months+113.98%
Current year+79.57%
More quotes
1 week
4.33
Extreme 4.332
4.74
1 month
2.50
Extreme 2.504
4.74
3 years
1.79
Extreme 1.794
15.97
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20/18/20
Chief Tech/Sci/R&D Officer 53 01/12
Chief Tech/Sci/R&D Officer 66 29/20/29
Members of the board TitleAgeSince
Director/Board Member 73 29/18/29
Chairman 61 30/22/30
Director/Board Member 59 22/19/22
More insiders
Date Price Change
07/24/07 4.378 -0.45%
06/24/06 4.398 -0.14%
05/24/05 4.404 -2.26%
04/24/04 4.506 -3.84%
03/24/03 4.686 +7.82%

Real-time BOERSE MUENCHEN, June 08, 2024 at 01:13 am IST

More quotes
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
51.15 SEK
Average target price
105 SEK
Spread / Average Target
+105.28%
Consensus